Log in

NASDAQ:MRKRTapImmune Stock Price, Forecast & News

+0.01 (+0.53 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $1.91
50-Day Range
MA: $2.21
52-Week Range
Now: $1.91
Volume255,200 shs
Average Volume335,544 shs
Market Capitalization$88.87 million
P/E RatioN/A
Dividend YieldN/A
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MRKR



Sales & Book Value

Annual Sales$210,000.00
Book Value$0.96 per share


Net Income$-21,430,000.00


Market Cap$88.87 million
Next Earnings Date8/13/2020 (Estimated)

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

TapImmune (NASDAQ:MRKR) Frequently Asked Questions

How has TapImmune's stock been impacted by COVID-19 (Coronavirus)?

TapImmune's stock was trading at $1.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRKR shares have decreased by 3.5% and is now trading at $1.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TapImmune?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TapImmune.

When is TapImmune's next earnings date?

TapImmune is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for TapImmune.

How were TapImmune's earnings last quarter?

TapImmune Inc. (NASDAQ:MRKR) posted its earnings results on Monday, May, 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. View TapImmune's earnings history.

What price target have analysts set for MRKR?

7 Wall Street analysts have issued 1-year target prices for TapImmune's stock. Their forecasts range from $2.50 to $16.00. On average, they expect TapImmune's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 397.4% from the stock's current price. View analysts' price targets for TapImmune.

Has TapImmune been receiving favorable news coverage?

News coverage about MRKR stock has been trending very negative this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TapImmune earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about TapImmune.

Who are some of TapImmune's key competitors?

What other stocks do shareholders of TapImmune own?

Who are TapImmune's key executives?

TapImmune's management team includes the following people:
  • Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)
  • Mr. Anthony H. Kim, Chief Financial Officer (Age 43)
  • Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)
  • Dr. Ann M. Leen, Chief Scientific Officer
  • Ms. Elizabeth Donnelly, Director of Admin.

What is TapImmune's stock symbol?

TapImmune trades on the NASDAQ under the ticker symbol "MRKR."

How do I buy shares of TapImmune?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TapImmune's stock price today?

One share of MRKR stock can currently be purchased for approximately $1.91.

How big of a company is TapImmune?

TapImmune has a market capitalization of $88.87 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. TapImmune employs 11 workers across the globe.

What is TapImmune's official website?

The official website for TapImmune is www.markertherapeutics.com.

How can I contact TapImmune?

TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.